Cargando…

One‐year persistent symptoms and functional impairment in SARS‐CoV‐2 positive and negative individuals

BACKGROUND: Persistent symptoms of SARS‐CoV‐2 are prevalent weeks to months following the infection. To date, it is difficult to disentangle the direct from the indirect effects of SARS‐CoV‐2, including lockdown, social, and economic factors. OBJECTIVE: The study aims to characterize the prevalence...

Descripción completa

Detalles Bibliográficos
Autores principales: Nehme, Mayssam, Braillard, Olivia, Chappuis, François, Courvoisier, Delphine S., Kaiser, Laurent, Soccal, Paola M., Reny, Jean‐Luc, Assal, Frederic, Bondolfi, Guido, Tardin, Aglaé, Graf, Christophe, Zekry, Dina, Stringhini, Silvia, Spechbach, Hervé, Jacquerioz, Frederique, Salamun, Julien, Lador, Frederic, Coen, Matteo, Agoritsas, Thomas, Benzakour, Lamyae, Favale, Riccardo, Genevay, Stéphane, Lauper, Kim, Meyer, Philippe, Poku, Nana K., Landis, Basile N., Baggio, Stéphanie, Grira, Marwène, Sandoval, José, Ehrsam, Julien, Regard, Simon, Genecand, Camille, Kopp, Garance, Guerreiro, Ivan, Allali, Gilles, Vetter, Pauline, Guessous, Idris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115262/
https://www.ncbi.nlm.nih.gov/pubmed/35555926
http://dx.doi.org/10.1111/joim.13482
_version_ 1784709915179220992
author Nehme, Mayssam
Braillard, Olivia
Chappuis, François
Courvoisier, Delphine S.
Kaiser, Laurent
Soccal, Paola M.
Reny, Jean‐Luc
Assal, Frederic
Bondolfi, Guido
Tardin, Aglaé
Graf, Christophe
Zekry, Dina
Stringhini, Silvia
Spechbach, Hervé
Jacquerioz, Frederique
Salamun, Julien
Lador, Frederic
Coen, Matteo
Agoritsas, Thomas
Benzakour, Lamyae
Favale, Riccardo
Genevay, Stéphane
Lauper, Kim
Meyer, Philippe
Poku, Nana K.
Landis, Basile N.
Baggio, Stéphanie
Grira, Marwène
Sandoval, José
Ehrsam, Julien
Regard, Simon
Genecand, Camille
Kopp, Garance
Guerreiro, Ivan
Allali, Gilles
Vetter, Pauline
Guessous, Idris
author_facet Nehme, Mayssam
Braillard, Olivia
Chappuis, François
Courvoisier, Delphine S.
Kaiser, Laurent
Soccal, Paola M.
Reny, Jean‐Luc
Assal, Frederic
Bondolfi, Guido
Tardin, Aglaé
Graf, Christophe
Zekry, Dina
Stringhini, Silvia
Spechbach, Hervé
Jacquerioz, Frederique
Salamun, Julien
Lador, Frederic
Coen, Matteo
Agoritsas, Thomas
Benzakour, Lamyae
Favale, Riccardo
Genevay, Stéphane
Lauper, Kim
Meyer, Philippe
Poku, Nana K.
Landis, Basile N.
Baggio, Stéphanie
Grira, Marwène
Sandoval, José
Ehrsam, Julien
Regard, Simon
Genecand, Camille
Kopp, Garance
Guerreiro, Ivan
Allali, Gilles
Vetter, Pauline
Guessous, Idris
author_sort Nehme, Mayssam
collection PubMed
description BACKGROUND: Persistent symptoms of SARS‐CoV‐2 are prevalent weeks to months following the infection. To date, it is difficult to disentangle the direct from the indirect effects of SARS‐CoV‐2, including lockdown, social, and economic factors. OBJECTIVE: The study aims to characterize the prevalence of symptoms, functional capacity, and quality of life at 12 months in outpatient symptomatic individuals tested positive for SARS‐CoV‐2 compared to individuals tested negative. METHODS: From 23 April to 27 July 2021, outpatient symptomatic individuals tested for SARS‐CoV‐2 at the Geneva University Hospitals were followed up 12 months after their test date. RESULTS: At 12 months, out of the 1447 participants (mean age 45.2 years, 61.2% women), 33.4% reported residual mild to moderate symptoms following SARS‐CoV‐2 infection compared to 6.5% in the control group. Symptoms included fatigue (16% vs. 3.1%), dyspnea (8.9% vs. 1.1%), headache (9.8% vs. 1.7%), insomnia (8.9% vs. 2.7%), and difficulty concentrating (7.4% vs. 2.5%). When compared to the control group, 30.5% of SARS‐CoV‐2 positive individuals reported functional impairment at 12 months versus 6.6%. SARS‐CoV‐2 infection was associated with the persistence of symptoms (adjusted odds ratio [aOR] 4.1; 2.60–6.83) and functional impairment (aOR 3.54; 2.16–5.80) overall, and in subgroups of women, men, individuals younger than 40 years, those between 40–59 years, and in individuals with no past medical or psychiatric history. CONCLUSION: SARS‐CoV‐2 infection leads to persistent symptoms over several months, including in young healthy individuals, in addition to the pandemic effects, and potentially more than other common respiratory infections. Symptoms impact functional capacity up to 12 months post infection.
format Online
Article
Text
id pubmed-9115262
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91152622022-05-18 One‐year persistent symptoms and functional impairment in SARS‐CoV‐2 positive and negative individuals Nehme, Mayssam Braillard, Olivia Chappuis, François Courvoisier, Delphine S. Kaiser, Laurent Soccal, Paola M. Reny, Jean‐Luc Assal, Frederic Bondolfi, Guido Tardin, Aglaé Graf, Christophe Zekry, Dina Stringhini, Silvia Spechbach, Hervé Jacquerioz, Frederique Salamun, Julien Lador, Frederic Coen, Matteo Agoritsas, Thomas Benzakour, Lamyae Favale, Riccardo Genevay, Stéphane Lauper, Kim Meyer, Philippe Poku, Nana K. Landis, Basile N. Baggio, Stéphanie Grira, Marwène Sandoval, José Ehrsam, Julien Regard, Simon Genecand, Camille Kopp, Garance Guerreiro, Ivan Allali, Gilles Vetter, Pauline Guessous, Idris J Intern Med Original Articles BACKGROUND: Persistent symptoms of SARS‐CoV‐2 are prevalent weeks to months following the infection. To date, it is difficult to disentangle the direct from the indirect effects of SARS‐CoV‐2, including lockdown, social, and economic factors. OBJECTIVE: The study aims to characterize the prevalence of symptoms, functional capacity, and quality of life at 12 months in outpatient symptomatic individuals tested positive for SARS‐CoV‐2 compared to individuals tested negative. METHODS: From 23 April to 27 July 2021, outpatient symptomatic individuals tested for SARS‐CoV‐2 at the Geneva University Hospitals were followed up 12 months after their test date. RESULTS: At 12 months, out of the 1447 participants (mean age 45.2 years, 61.2% women), 33.4% reported residual mild to moderate symptoms following SARS‐CoV‐2 infection compared to 6.5% in the control group. Symptoms included fatigue (16% vs. 3.1%), dyspnea (8.9% vs. 1.1%), headache (9.8% vs. 1.7%), insomnia (8.9% vs. 2.7%), and difficulty concentrating (7.4% vs. 2.5%). When compared to the control group, 30.5% of SARS‐CoV‐2 positive individuals reported functional impairment at 12 months versus 6.6%. SARS‐CoV‐2 infection was associated with the persistence of symptoms (adjusted odds ratio [aOR] 4.1; 2.60–6.83) and functional impairment (aOR 3.54; 2.16–5.80) overall, and in subgroups of women, men, individuals younger than 40 years, those between 40–59 years, and in individuals with no past medical or psychiatric history. CONCLUSION: SARS‐CoV‐2 infection leads to persistent symptoms over several months, including in young healthy individuals, in addition to the pandemic effects, and potentially more than other common respiratory infections. Symptoms impact functional capacity up to 12 months post infection. John Wiley and Sons Inc. 2022-03-31 2022-07 /pmc/articles/PMC9115262/ /pubmed/35555926 http://dx.doi.org/10.1111/joim.13482 Text en © 2022 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is noncommercial and no modifications or adaptations are made.
spellingShingle Original Articles
Nehme, Mayssam
Braillard, Olivia
Chappuis, François
Courvoisier, Delphine S.
Kaiser, Laurent
Soccal, Paola M.
Reny, Jean‐Luc
Assal, Frederic
Bondolfi, Guido
Tardin, Aglaé
Graf, Christophe
Zekry, Dina
Stringhini, Silvia
Spechbach, Hervé
Jacquerioz, Frederique
Salamun, Julien
Lador, Frederic
Coen, Matteo
Agoritsas, Thomas
Benzakour, Lamyae
Favale, Riccardo
Genevay, Stéphane
Lauper, Kim
Meyer, Philippe
Poku, Nana K.
Landis, Basile N.
Baggio, Stéphanie
Grira, Marwène
Sandoval, José
Ehrsam, Julien
Regard, Simon
Genecand, Camille
Kopp, Garance
Guerreiro, Ivan
Allali, Gilles
Vetter, Pauline
Guessous, Idris
One‐year persistent symptoms and functional impairment in SARS‐CoV‐2 positive and negative individuals
title One‐year persistent symptoms and functional impairment in SARS‐CoV‐2 positive and negative individuals
title_full One‐year persistent symptoms and functional impairment in SARS‐CoV‐2 positive and negative individuals
title_fullStr One‐year persistent symptoms and functional impairment in SARS‐CoV‐2 positive and negative individuals
title_full_unstemmed One‐year persistent symptoms and functional impairment in SARS‐CoV‐2 positive and negative individuals
title_short One‐year persistent symptoms and functional impairment in SARS‐CoV‐2 positive and negative individuals
title_sort one‐year persistent symptoms and functional impairment in sars‐cov‐2 positive and negative individuals
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115262/
https://www.ncbi.nlm.nih.gov/pubmed/35555926
http://dx.doi.org/10.1111/joim.13482
work_keys_str_mv AT nehmemayssam oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT braillardolivia oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT chappuisfrancois oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT courvoisierdelphines oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT kaiserlaurent oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT soccalpaolam oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT renyjeanluc oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT assalfrederic oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT bondolfiguido oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT tardinaglae oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT grafchristophe oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT zekrydina oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT stringhinisilvia oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT spechbachherve oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT jacqueriozfrederique oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT salamunjulien oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT ladorfrederic oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT coenmatteo oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT agoritsasthomas oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT benzakourlamyae oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT favalericcardo oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT genevaystephane oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT lauperkim oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT meyerphilippe oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT pokunanak oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT landisbasilen oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT baggiostephanie oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT griramarwene oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT sandovaljose oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT ehrsamjulien oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT regardsimon oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT genecandcamille oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT koppgarance oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT guerreiroivan oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT allaligilles oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT vetterpauline oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT guessousidris oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals
AT oneyearpersistentsymptomsandfunctionalimpairmentinsarscov2positiveandnegativeindividuals